Role of oxidative stress and inflammation in the origin of Type 2 diabetes – a paradigm shift

Bibliography

• NARAYAN KM, BOYLE JP, THOMPSON TJ, SORENSEN SW, WILLIAMSON DF: Lifetime risk for diabetes mellitus in the United States. JAMA (2003) 290(14):1884–1890.
   PubMed Web of Science ®Google Scholar
• BELL DS: Type 2 diabetes mellitus: what is the optimal treatment regimen? Am. I Med. (2004) 116(Suppl. 5A):235–295.
   Google Scholar
• RAPTIS SA, DIMITRIADIS GD: Oral hypoglycemic agents: insulin secretagogues, a-glucosidase inhibitors and insulin sensitizers. Exp. Clin. Endocrinol. Diabetes (2001) 109\(Suppl. 2):5265–5287.
   Google Scholar
• VOLLENWEIDER PR: Insulin resistant states and insulin signaling. Clin. Chem. Lab. Med. (2003) 41(9):1107–1119.
   PubMedGoogle Scholar
• KADENBACH B: Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim. Biophys. Acta (2003) 1604(2):77–94.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA T, EDELSTEIN D, DU XL et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404(6779):787–790.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the link betweenmitochondrial superoxide and diabetic vascular complications.
   Google Scholar
• BEBERNITZ GR, SCHUSTER HF: The impact of fatty acid oxidation on energy utilization: targets and therapy. Carr. Pharm. Des. (2002) 8(14):1199–1227.
   PubMedGoogle Scholar
• MCGARRY JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes. Diabetes (2002) 51(1):7–18.
   PubMed Web of Science ®Google Scholar
• PETERSEN KF, BEFROY D, DUFOUR S et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science (2003) 300(5622):1140–1142.
   PubMed Web of Science ®Google Scholar
• ••Study linking mitochondrial dysfunction toinsulin resistance in humans.
   Google Scholar
• PETERSEN KF, DUFOUR S, BEFROY D, GARCIA R, SHULMAN GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with Type 2 diabetes. N Engl. Med. (2004) 350(7):664–671.
   PubMed Web of Science ®Google Scholar
• KRAUSS S, ZHANG CY, SCORRANO L et al.: Superoxide-mediated activation of uncoupling protein 2 causes pancreatic 13 cell dysfunction. Clin. Invest. (2003) 112(12):1831–1842.
   Google Scholar
• •Demonstrates the critical role for UCP-2 in superoxide-induced 13 cell dysfunction.
   Google Scholar
• LAMELOISE N, MUZZIN P, PRENTKI M, ASSIMACOPOULOS-JEANNET F: Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes (2001) 50(4):803–809.
   PubMedGoogle Scholar
• ZHANG CY, BAFFY G, PERRET P et al: Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, 13 cell dysfunction, and Type 2 diabetes. Cell (2001) 105(6):745–755.
   PubMed Web of Science ®Google Scholar
• ZONG H, REN JM, YOUNG LH et al: AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. USA (2002) 99(25):15983–15987.
   PubMed Web of Science ®Google Scholar
• ATTIE AD, KENDZIORSKI CM: PGC- la at the crossroads of Type 2 diabetes. Nat. Genet. (2003) 34(3):244–245.
   PubMedGoogle Scholar
• MOOTHA VK, LINDGREN CM, ERIKSSON KF et al.: PGC- la-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. (2003) 34(3):267–273.
   PubMed Web of Science ®Google Scholar
• PATTI ME, BUTTE AJ, CRUNKHORN S et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad Sci. USA (2003) 100(14):8466–8471.
   PubMed Web of Science ®Google Scholar
• LEVERVE XM, GUIGAS B, DETAILLE D et al.: Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab. (2003) 29(4 Pt 2):6S88-6S94.
   Google Scholar
• KARIN M, TAKAHASHI T, KAPAHI P et al.: Oxidative stress and gene expression: the AP-1 and NFicB connections. Biofactors (2001) 15(2-4):87–89.
   PubMedGoogle Scholar
• HADDAD JJ: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell. Signal (2002) 14(11):879–897.
   PubMed Web of Science ®Google Scholar
• JASPERS I, ZHANG W, FRASER A, SAMET JM, REED W: Hydrogen peroxide has opposing effects on IKK activity and IB breakdown in airway epithelial cells. Am. .1. Respic Cell Mol. Biol. (2001) 24:769–777.
   PubMed Web of Science ®Google Scholar
• YUAN M, KONSTANTOPOULOS N, LEE J et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkl3. Science (2001) 293(5535):1673–1677.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates a crucial role for IKK ininsulin resistance.
   Google Scholar
• HUNDAL RS, PETERSEN KF, MAYERSON AB et al.: Mechanism by which high-dose aspirin improves glucose metabolism in Type 2 diabetes. J. Clin. Invest. (2002) 109(10):1321–1326.
   PubMed Web of Science ®Google Scholar
• GAO Z, ZUBERI A, QUON MJ, DONG Z, YE J: Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J. Biol. Chem. (2003) 278(27):24944–24950.
   PubMed Web of Science ®Google Scholar
• PERSEGHIN G, PETERSEN K, SHULMAN GI: Cellular mechanism of insulin resistance: potential links with inflammation. Int. I Obes. Relat. Metab. Disord. (2003) 27\(Suppl. 3):56–S11.
   Google Scholar
• PRADHAN AD, RIDKER PM: Do atherosclerosis and Type 2 diabetes share a common inflammatory basis? Ear: Heart (2002) 23:831–834.
   Google Scholar
• DANDONA P, ALJADA A, BANDYOPADHYAY A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. (2004) 25(1):4–7.
   PubMed Web of Science ®Google Scholar
• PRADHAN AD, MANSON JE, RIFAI N, BURING JE, RIDKER PM: C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA (2001) 286:327–334.
   PubMed Web of Science ®Google Scholar
• ••Prospective, case-control studydemonstrating that elevated levels of CRP and IL-6 predict the development of Type 2 diabetes.
   Google Scholar
• Expert Op/n. Ther. Targets (2004) 8(5)
   Google Scholar
• HOTAMISLIGIL GS, ARNER P, CARO JF, ATKINSON RL, SPIEGELMAN BM: Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. I Clin. Invest. (1995) 95:2409–2415.
   PubMed Web of Science ®Google Scholar
• NILSSON J, JOVINGE S, NIEMANN A, RENELAND R, LITHELL H: Relation between plasma tumor necrosis factor-a and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscier. Thrornb. Vase. Biol. (1998) 18:1199–1202.
   PubMed Web of Science ®Google Scholar
• LIU ZG: Adding facets to TNF signaling. The JNK angle. MM. Cell (2003) 12(4):795–796.
   PubMedGoogle Scholar
• HIROSUMI J, TUNCMAN G, CHANG L et al.: A central role for JNK in obesity and insulin resistance. Nature (2002) 420(6913):333–336.
   PubMed Web of Science ®Google Scholar
• •Study demonstrates a central role for JNK in insulin resistance.
   Google Scholar
• BENNETT BL, SATOH Y, LEWIS AJ: JNK: a new therapeutic target for diabetes. Curr: Opin. Pharmacol (2003) 3(4):420–425.
   PubMed Web of Science ®Google Scholar
• AGUIRRE V, UCHIDA T, YENUSH L, DAVIS R, WHITE MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. (2000) 275:9047–9054.
   PubMed Web of Science ®Google Scholar
• WASSMANN S, STUMPF M, STREHLOW K et al.: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II Type 1 receptor. Circ. Res. (2004) 94(4):534–541.
   PubMed Web of Science ®Google Scholar
• GOOSSENS V, GROOTEN J, DE VOS K et al.: Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl. Acad. Sci. USA (1995) 92:8115–8119.
   Google Scholar
• CORDA S, LAPLACE C, VICAUT E et al.: Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-a is mediated by ceramide. Am. I Respir. Cell MM. Biol. (2001) 24:762–768.
   PubMed Web of Science ®Google Scholar
• MONTONEN J, KNEKT P, JARVINEN R, REUNANEN A: Dietary antioxidant intake and risk of Type 2 diabetes. Diabetes Care (2004) 27(2):362–366.
   PubMed Web of Science ®Google Scholar
• FESKENS EJ, VIRTANEN SM, WASANEN L et al.: Dietary factors determining diabetes and impaired glucose tolerance: a 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care (1995) 18:1104–1112.
   PubMed Web of Science ®Google Scholar
• SALONEN JT, NYYSSONEN K, TUOMAINEN TP et al.: Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. Br. Med. (1995) 311:1124–1127.
   PubMed Web of Science ®Google Scholar
• KNEKT P, REUNANEN A, MARNIEMI J, LEINO A, AROMAA A: Low vitamin E status is a potential risk factor for insulin-dependent diabetes mellitus.' Intern. Med. (1999) 245:99–102.
   Google Scholar
• CHATTERJEE IB, BANERJEE A: Estimation of dehydroascorbic acid in blood of diabetic patients. Anal. Biochem. (1979) 98:368–374.
   PubMed Web of Science ®Google Scholar
• SINCLAIR AJ, TAYLOR PB, LUNEC J,GIRLING AJ, BARNETT AH: Low plasma ascorbate levels in patients with Type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet. Med. (1994) 11:893–898.
   PubMed Web of Science ®Google Scholar
• WILL JC, FORD ES, BOWMAN BA: Serum vitamin C concentrations and diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. An7.1 Clin. Num. (1999) 70:49–52.
   PubMed Web of Science ®Google Scholar
• ABAHUSAIN MA, WRIGHT J, DICKERSON RV, DE VOL EB: Retinol, a-tocopherol and carotenoids in diabetes. Eur. Gin. Num. (1999) 53:630–635.
   PubMed Web of Science ®Google Scholar
• FORD ES, WILL JC, BOWMAN BA, NARAYAN KM: Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey. Am. I Epidemiol (1999) 149:168–176.
   PubMed Web of Science ®Google Scholar
• POLIDORI MC, MECOCCI P, STAHL W et al.: Plasma levels of lipophilic antioxidants in very old patients with Type 2 diabetes. Diabetes Metab. Res. Rev (2000) 16:15–19.
   PubMed Web of Science ®Google Scholar
• SARGEANT LA, WAREHAM NJ, BINGHAM S et al.: Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care (2000) 23:726–732.
   PubMed Web of Science ®Google Scholar
• PARTHASARATHY S, KHAN-MERCHANT N, PENUMETCHA M, KHAN BV, SANTANAM N: Did the antioxidant trials fail to validate the oxidation hypothesis? Curt-. Atheroscler. Rep. (2001) 3:392–398.
   PubMedGoogle Scholar
• CERIELLO A, MOTZ E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. ilrteriosc/er. Thrornb. Vase. Biol. (2004) 24(5):816–823.
   PubMed Web of Science ®Google Scholar
• LAMBETH JD: NOX enzymes and the biology of reactive oxygen. Nat. Rev Immunol (2004) 4(3):181–189.
   PubMed Web of Science ®Google Scholar
• SONTA T, INOGUCHI T, TSUBOUCHI H et al.: Evidence for contribution of vascular NAD(P)H wddase to increased oxidative stress in animal models of diabetes and obesity. Free Radic. Biol. Med. (2004) 37:115–123.
   PubMed Web of Science ®Google Scholar
• THABUT G, EL-BENNA J, SAMB A et al.: Tumor necrosis factor-a increases airway smooth muscle oxidants production through a NADPH wddase-like system to enhance myosin light chain phosphorylation and contractility." Biol. Chem. (2002) 277:22814–22821.
   Google Scholar
• LI JM, MULLEN AM, YUN S et al: Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-a. Circ. Res. (2002) 90:143–150.
   PubMed Web of Science ®Google Scholar
• INOGUCHI T, TSUBOUCHI H, ETOH T et al.: A possible target of antioxidative therapy for diabetic vascular complications-vascular NAD(P)H wddase. Curt-. Med. Chem. (2003) 10(17):1759–1764.
   PubMedGoogle Scholar
• YAMAGISHI S, INAGAKI Y, KIKUCHI S: Nifedipine inhibits tumor necrosis factor-a-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH wddase-mediated reactive oxygen species generation. Drugs Exp. Clin. Res. (2003) 29:147–152.
   PubMedGoogle Scholar
• YAMAGISHI S, INAGAKI Y, NAKAMURA K, IMAIZUMI T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-a-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J. Cardiovasc. Pharmacol (2004) 43:724–730.
   PubMed Web of Science ®Google Scholar
• MATES JM, SANCHEZ-JIMENEZ F: Antioxidant enzymes and their implications in pathophysiologic processes. Front. Biosci. (1999) 15:D339–D345.
   Google Scholar
• RHEE SG, CHANG TS, BAE YS, LEE SR, KANG SW: Cellular regulation by hydrogen peroxide. j. Am. Soc. Nephrol (2003) 14(8 Suppl. 3):S211–S215.
   Google Scholar
• KITANI K, MINAMI C, MARUYAMA W, KANAI S, IVY GO, CARRILLO MC: Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl..1. Neural Bansm. Sapp]. (2000) 60:139–156.
   Google Scholar
• GIBLIN GM, BOX PC, CAMPBELL TB et al.: 6,6'-Bis(2-hydroxypheny1)-2,2'-bipyridine manganese(III) complexes: a novel series of superoxide dismutase and catalase mimetics. Bioorg. Med. Chem. Lett. (2001) 11(11):1367–1370.
   PubMedGoogle Scholar
• MELOV S, RAVENSCROFT J, MALIK S et al.: Extension of life-span with superoxide dismutase/catalase mimetics. Science (2000) 289(5484):1567–1569.
   PubMedGoogle Scholar
• LIU R, LIU IY, BI X etReversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc. Natl. Acad. Sci. USA (2003) 100(14):8526–8531.
   PubMed Web of Science ®Google Scholar
• BAST A, HAENEN GR: Lipoic acid: a multifunctional antioxidant. Biofactors (2003) 17(1-4):207–213.
   PubMed Web of Science ®Google Scholar
• EVANS JL, GOLDFINE ID: a-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with Type 2 diabetes. Diabetes Technol Then (2000) 2:401–413.
   PubMedGoogle Scholar
• JACOB S, RUUS P, HERMANN R et Oral administration of RAC-a-lipoic acid modulates insulin sensitivity in patients with Type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic. Biol. Med. (1999) 27:309–314.
   PubMed Web of Science ®Google Scholar
• OFEI F, HUREL S, NEWKIRK J, SOPWITH M, TAYLOR R: Effects of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes (1996) 45:881–885.
   PubMed Web of Science ®Google Scholar
• EVANS JL, GOLDFINE ID, MADDUX BA, GRODSKY GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and 13-cell dysfunction? Diabetes (2003) 52:1–8.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP, HARMON J, IRAN PO, POITOUT V: I3-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in Type 2 diabetes. Diabetes (2004) 53:S119–S124.
   PubMedGoogle Scholar